Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL TO STUDY THE VIASKIN MILK EFFICACY AND SAFETY FOR TREATING IGE-MEDIATED COW'S MILK ALLERGY IN CHILDREN

Intervention/treatment:
VIASKIN MILK (DBV135)
Medical condition:
ALLERGIES ENVIRONMENTAL
Protocol code:
MILES
Control number:
176048
Status:
Closed
Approved:
August 08, 2014
Date Completed:
Trial phase:
Phase 1, Phase 2
For more information:
ClinicalTrials.gov - NCT02223182
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
2 Years to 17 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pharis Mohideen, MD Chief Medical Officer
Organization
DBV Technologies
Phone:
908-679-5200
Sponsor
DBV TECHNOLOGIES SA

Locations

Clinique Spécialisée en allergie de la Capitale
Québec, G1V 4W2

Ontario

Cheema Research Inc.
Mississauga, Ontario, L5A 3V4
Gordon Sussman Clinical Research Inc.
Toronto, Ontario, M4V 1R2
Ottawa Allergy Research Corporation
Ottawa, Ontario, K1G6C6

Quebec

Centre Hospitalier Universitaire Sainte Justine
Montreal, Quebec, H3T 1C4

Results

See the results from the trial NCT02223182. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?